Suscribirse

Post-Discharge Worsening Renal Function in Patients with Type 2 Diabetes and Recent Acute Coronary Syndrome - 23/08/17

Doi : 10.1016/j.amjmed.2017.02.033 
Nuccia Morici, MD a, , Stefano Savonitto, MD b, Claudio Ponticelli, MD c, Ilse C. Schrieks, PhD, MSc d, Anna Nozza, MSc e, Francesco Cosentino, MD f, Barbara E. Stähli, MD g, Pasquale Perrone Filardi, MD h, Gregory G. Schwartz, MD i, Linda Mellbin, MD f, A. Michael Lincoff, MD j, Jean-Claude Tardif, MD e, g, Diederick E. Grobbee, MD d
a Unità di Terapia Intensiva Cardiologica, ASST Grande Ospedale Metropolitano Niguarda Ca' Granda, Milano, Italy 
b Dipartimento Cardiovascolare, Ospedale A. Manzoni, Lecco, Italy 
c Division of Nephrology, Humanitas Clinical Research Center, Rozzano (Milano), Italy 
d Julius Center for Health Sciences and Primary Care and Julius Clinical, Utrecht, the Netherlands 
e Montreal Health Innovations Coordinating Center, Quebec, Canada 
f Cardiology Unit, Department of Medicine, Karolinska University Hospital, Stockholm, Sweden 
g Montreal Heart Institute, Université de Montréal, Quebec, Canada 
h Department of Advanced Biomedical Sciences, Federico II University, Naples, Italy 
i Veterans Affairs Medical Center and University of Colorado School of Medicine, Denver 
j Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Ohio 

Requests for reprints should be addressed to Nuccia Morici, MD, Unità di Terapia Intensiva Cardiologica, ASST Grande Ospedale Metropolitano Niguarda, Piazza Ospedale Maggiore 3, Milan 20162, Italy.Unità di Terapia Intensiva CardiologicaASST Grande Ospedale Metropolitano NiguardaPiazza Ospedale Maggiore 3Milan20162Italy

Abstract

Background

Worsening renal function during hospitalization for an acute coronary syndrome is strongly predictive of in-hospital and long-term outcome. However, the role of post-discharge worsening renal function has never been investigated in this setting.

Methods

We considered the placebo cohort of the AleCardio trial comparing aleglitazar with standard medical therapy among patients with type 2 diabetes mellitus and a recent acute coronary syndrome. Patients who had died or had been admitted to hospital for heart failure before the 6-month follow-up, as well as patients without complete renal function data, were excluded, leaving 2776 patients for the analysis. Worsening renal function was defined as a >20% reduction in estimated glomerular filtration rate from discharge to 6 months, or progression to macroalbuminuria. The Cox regression analysis was used to determine the prognostic impact of 6-month renal deterioration on the composite of all-cause death and hospitalization for heart failure.

Results

Worsening renal function occurred in 204 patients (7.34%). At a median follow-up of 2 years the estimated rates of death and hospitalization for heart failure per 100 person-years were 3.45 (95% confidence interval [CI], 2.46-6.36) for those with worsening renal function, versus 1.43 (95% CI, 1.14-1.79) for patients with stable renal function. At the adjusted analysis worsening renal function was associated with the composite endpoint (hazard ratio 2.65; 95% CI, 1.57-4.49; P <.001).

Conclusions

Post-discharge worsening renal function is not infrequent among patients with type 2 diabetes and acute coronary syndromes with normal or mildly depressed renal function, and is a strong predictor of adverse cardiovascular events.

El texto completo de este artículo está disponible en PDF.

Keywords : Acute coronary syndrome, Diabetes mellitus, Worsening renal function


Esquema


 Funding: None.
 Conflict of Interest: There has been no significant financial support for this particular work that could have influenced its outcome.
 Authorship: All authors had access to the data and a role in writing the manuscript.


© 2017  Elsevier Inc. Reservados todos los derechos.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 130 - N° 9

P. 1068-1075 - septembre 2017 Regresar al número
Artículo precedente Artículo precedente
  • Early Invasive Versus Initial Conservative Strategies for Women with Non–ST-Elevation Acute Coronary Syndromes: A Nationwide Analysis
  • Islam Y. Elgendy, Ahmed N. Mahmoud, Hend Mansoor, Anthony A. Bavry
| Artículo siguiente Artículo siguiente
  • Single High-Sensitivity Cardiac Troponin I to Rule Out Acute Myocardial Infarction
  • Yader Sandoval, Stephen W. Smith, Sara A. Love, Anne Sexter, Karen Schulz, Fred S. Apple

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

@@150455@@ Voir plus

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2025 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.